RESEARCH PAPER

Thromboxane A₂ inhibition of SK_{Ca} after NO synthase block in rat middle cerebral artery

AJ McNeish and CJ Garland

Department of Pharmacy and Pharmacology, the University of Bath, Claverton Down, Bath, UK

Background and purpose: NO/prostanoid independent, EDHF-mediated hyperpolarization and dilation in rat middle cerebral arteries is mediated solely by endothelial cell IK_{Ca} . However, when the NO-pathway is also active, both SK_{Ca} and IK_{Ca} contribute to EDHF responses. As the SK_{Ca} component can be inhibited by stimulation of thromboxane A_2 (TxA₂) TP receptors and NO has the potential ability to inhibit thromboxane synthesis, we investigated whether TxA₂ might explain loss of functional input from SK_{Ca} during NOS inhibition in cerebral arteries.

Experimental approach: Rat middle cerebral arteries were mounted in a wire myograph. Endothelium-dependent responses to the PAR2 agonist, SLIGRL were assessed as simultaneous changes in smooth muscle membrane potential and tension.

Key results: Responses were obtained in the presence of L-NAME as appropriate. Inhibition of TP receptors with either ICI 192,605 or SQ 29,548, did not affect EDHF mediated hyperpolarization and relaxation, but in their presence neither TRAM-34 nor apamin (to block IK_{Ca} and SK_{Ca} respectively) individually affected the EDHF response. However, in combination they virtually abolished it. Similar effects were obtained in the presence of the thromboxane synthase inhibitor, furegrelate, which additionally revealed an iberiotoxin-sensitive residual EDHF hyperpolarization and relaxation in the combined presence of TRAM-34 and apamin.

Conclusions and implications: In the rat middle cerebral artery, inhibition of NOS leads to a loss of the SK_{Ca} component of EDHF responses. Either antagonism of TP receptors or block of thromboxane synthase restores an input through SK_{Ca} . These data indicate that NO normally enables SK_{Ca} activity in rat middle cerebral arteries.

British Journal of Pharmacology (2007) 151, 441-449; doi:10.1038/sj.bjp.0707240; published online 10 April 2007

Keywords: thromboxane A₂; small conductance calcium-activated potassium channel; intermediate conductance calciumactivated potassium channel; large conductance calcium-activated potassium channel; endothelium-derived hyperpolarizing factor, nitric oxide, cerebral artery

Abbreviations: 20-HETE, 20-hydroxy-(5*Z*,8*Z*,11*Z*,14*Z*)-eicosatetraenoic acid; 17-ODYA, 17-octadecynoic acid; BK_{Ca}, large conductance calcium-activated potassium channel; CYP450, cytochrome *P*450; EDHF, endothelium-derived hyperpolarizing factor; EETs, epoxyeicosatrienoic acids; HETEs, hydroxyeicosatetraenoic acids; IK_{Ca}, intermediate conductance calcium-activated potassium channel; NOS, nitric oxide synthase; ODQ, 1*H*-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one; PAR2, protease activated receptor 2; PKG, protein kinase G; SK_{Ca}, small conductance calcium-activated potassium channel; TRAM-34, 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole; TxA2, thromboxane A₂; TP, thromboxane A₂ receptor

Introduction

In rat middle cerebral arteries treated with a nitric oxide synthase (NOS) inhibitor (L-NAME (N^{G} -nitro-L-arginine methyl ester)), blockade of the intermediate conductance calcium-activated potassium channels (IK_{Ca}) in endothelial cells alone is sufficient to block smooth muscle hyperpolarization and relaxation due to endothelium-derived hyperpolarizing factor (EDHF; Marrelli *et al.*, 2003; McNeish *et al.*, 2005). This is in contrast to peripheral arteries, where EDHF-

mediated responses are only abolished by the combined inhibition of both small conductance calcium-activated potassium channels (SK_{Ca}) and IK_{Ca} (Busse *et al.*, 2002). A number of studies with peripheral arteries have provided functional, electrophysiological and immunohistochemical data showing that SK_{Ca} and IK_{Ca} channels are expressed only within the endothelium (Walker *et al.*, 2001; Burnham *et al.*, 2002; Bychkov *et al.*, 2002). We recently investigated if the apparent solitary role of IK_{Ca} in the EDHF response of rat middle cerebral arteries reflected an absence of SK_{Ca} channels. Surprisingly in the light of the functional data, but in common with peripheral arteries, both IK_{Ca} and SK_{Ca} channels were demonstrated in the endothelium (McNeish *et al.*, 2006).

Correspondence: Professor CJ Garland, Department of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK. E-mail: c.j.garland@bath.ac.uk

Received 26 October 2006; revised 25 January 2007; accepted 22 February 2007; published online 10 April 2007

The relative contribution from SK_{Ca} and IK_{Ca} channels to the EDHF response depends on the state of the arterial smooth muscle. In rat mesenteric arteries, during smooth muscle contraction evoked by phenylephrine, block of endothelium-dependent hyperpolarization and relaxation requires inhibition of both endothelial SK_{Ca} and IK_{Ca} , but in unstimulated vessels (where there is no contraction to reverse) inhibition of SK_{Ca} alone is sufficient to block EDHF-mediated hyperpolarization (Crane et al., 2003). In contrast to mesenteric arteries, arterial stimulation may not regulate K_{Ca} function in middle cerebral arteries, as increases in stretch-induced tension did not alter SK_{Ca} input (McNeish et al., 2006). However, basal release of NO suppresses myogenic tone, and an ability to elaborate NO is associated with maintained SK_{Ca} input to EDHF-evoked hyperpolarization in this artery. It is only after inhibition of NO synthase that the contribution of SK_{Ca} is lost, with EDHF responses becoming entirely reliant on IK_{Ca} (McNeish et al., 2005, 2006).

Although NO may suppress EDHF activity under some circumstances, these two separate dilator pathways do operate simultaneously in many arteries, including the rat middle cerebral artery (Zygmunt et al., 1998; Feletou and Vanhoutte, 2006; McNeish et al., 2006), but it is not clear how NO may alter SK_{Ca} activity. In non-vascular smooth muscle from the rat, there is evidence that NO can directly stimulate SK_{Ca} channel function (Geeson et al., 2002). Basal release of NO may also protect SK_{Ca} channel function indirectly. For example, NO may suppress an inhibitory mediator for the $SK_{\mbox{\scriptsize Ca}}$ channel (and thus the EDHF response) such as the potent vasoconstrictor 20-HETE (20-hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoic acid). 20-HETE does inhibit the EDHF response in small porcine coronary arteries (Randriamboavonjy et al., 2005) and NO can inhibit the synthesis of 20-HETE, by binding to the haem group of cytochrome P450 (CYP450) (Minamiyama et al., 1997). Another mediator that could potentially affect the EDHF response and in particular the SK_{Ca} channel is thromboxane A₂ (TxA₂). In rat mesenteric resistance arteries, stimulation of TxA₂ receptors (TP receptors) with U46619 (9,11-dideoxy- $11\alpha,9\alpha$ -epoxymethanoprostaglandin F2 α) attenuates SK_{Ca} function (Crane and Garland, 2004). NO has also been shown to inhibit the synthesis of TxA₂, again by an interaction with a haem active site, this time in thromboxane synthase (Wade and Fitzpatrick, 1997). Indeed, increased TxA₂ signalling has been reported to contribute to vasoconstriction and the development of vasomotion induced in middle cerebral arteries by NO synthase inhibitors (Benyo et al., 1998; Lacza et al., 2001). Finally, NO may also affect K_{Ca} function via indirect cGMP-mediated effects. So, for example, NO/cyclic 3',5'-guanosine monophosphate (cGMP) causes desensitization of TP receptors via a protein kinase G (PKG)-dependent mechanism (Reid and Kinsella, 2003).

Therefore, we hypothesized that constriction following inhibition of NOS and the associated loss of the SK_{Ca} component of agonist-induced hyperpolarization may be underpinned by an increase in the synthesis and/or function of TxA_2 or 20-HETE in the rat middle cerebral artery. The aim of the present study was therefore to assess the contribution of K_{Ca} channel subtypes to hyperpolarization and relaxation

in rat middle cerebral artery smooth muscle cells by stimulating the endothelium with the protease activated receptor 2 (PAR2) receptor agonist, SLIGRL; SLIGRL was the only agent used to stimulate endothelium-dependent responses as other mediators such as acetylcholine (ACh), adenosine diphosphate (ADP) and bradykinin elicit a much less reliable EDHF response in middle cerebral arteries (unpublished data). Subsequently, we investigated whether inhibiting TP receptors, thromboxane synthesis or synthesis of 20-HETE can restore the SK_{Ca} component of the EDHF response that is lost after inhibition of NOS. The ability of these treatments to reverse the L-NAME induced depolarization and constriction was also evaluated.

Methods

Male Wistar rats (200–300 g) were killed by cervical dislocation and the brains removed and immediately placed in icecold Krebs solution. Segments of the middle cerebral artery ($\sim 2 \text{ mm}$ long) were dissected and stored in ice-cold Krebs solution for use within 30 min, with similar size vessels used in all experimental groups

Experimental protocols

Segments of middle cerebral artery (internal diameter \sim 150 μ m) were mounted in a Mulvany-Halpern myograph (model 400A, Danish Myotechnology) in Krebs solution containing (mM): NaCl, 118.0, NaCO₃, 24; KCl, 3.6; MgSO₄·7H₂O, 1.2; glucose, 11.0; CaCl₂, 2.5; gassed with 95% O₂ and 5% CO₂ and maintained at 37°C. After equilibration for 20 min, vessels were tensioned to 1–1.5 mN (approximates wall tension at 60 mm Hg). Smooth muscle tension was recorded with an isometric pressure transducer and Powerlab software (ADI, Australia). Vessel viability was assessed by adding exogenous K^+ (15–55 mM, total K⁺ concentration); only vessels developing tension of \geq 3 mN were used. Endothelial cell viability was assessed by the ability of SLIGRL (20 μ M) to relax myogenic tone and to hyperpolarize the smooth muscle cell membrane by $> 15 \, {\rm mV}.$

All EDHF responses to SLIGRL (20 μ M) were obtained in the presence of L-NAME (100 μ M) to block NOS, unless otherwise stated. EDHF-mediated responses were assessed in the presence of the K_{Ca} channel blockers, apamin (SK_{Ca}, 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole 50 nm), (TRAM-34) (IK_{Ca}, 1μ M) and iberiotoxin (large conductance calcium-activated potassium channel (BK_{Ca}), 100 nM). The effect of K_{Ca} blockers on EDHF-mediated responses was also assessed after addition of the TP receptor antagonists SQ 29,548 (10 μ M) and ICI 192,605 (100 μ M); the TxA₂ synthase inhibitor, furegrelate ($10 \mu M$); the cyclo-oxygenase inhibitor, indomethacin (10 μ M) and the phospholipase A₂ inhibitor, AACOCF₃ (10 μ M). In some experiments, endotheliumdependent hyperpolarization was assessed in vessels without L-NAME and still able to synthesize NO. In these experiments, the effect of the K_{Ca} channel blockers was assessed on endothelium-dependent hyperpolarization induced by SLIGRL (20 μ M) in the presence of the TP receptor agonist U46619 (5 nM). Papaverine (150 μ M) was added at the end of each experiment to assess overall tone. All drugs were allowed to equilibrate for at least 20 min before vasodilator responses were stimulated. In most experiments, smooth muscle membrane potential ($E_{\rm m}$) and tension were measured simultaneously as previously described, using glass microelectrodes (filled with 2 m KCl; tip resistance, 80–120 M Ω) to measure $E_{\rm m}$ (Garland and McPherson, 1992).

Data analysis and statistical procedures

Results are expressed as the mean±s.e.m. of *n* animals. Tension values are given in mN (always per 2 mm segment) and $E_{\rm m}$ as mV. Vasodilatation is expressed as percentage reduction of the total vascular tone (myogenic tone plus vasoconstrictor response), quantified by relaxation with papaverine (150 μ M). Graphs were drawn and comparisons made using one-way analysis of variance with Tukeys' posttest (Prism, Graphpad). $P \leq 0.05$ was considered significant.

Drugs, chemicals, reagents and other materials

Exogenous K⁺ was added as an isotonic physiological salt solution in which all the NaCl was replaced with an equivalent amount of KCl. Concentrations of K⁺ used are expressed as final bath concentration. AACOCF3 (1,1,1-Trifluoromethyl-6,9,12,15-heieicosatetraen-2-one), L-NAME, papaverine HCl and U46619 were all obtained from Sigma (Poole, UK); apamin and iberotoxin, from Latoxan (Valence, France); ICI 192,605 (4(Z)-6-(2-o-chlorophenyl-4-o-hydroxyphenyl-1,3-dioxan-cis-5-yl)hexenoic acid) from Tocris (Nottingham, UK); SLIGRL (serine, leucine, isoleucine, glycine, arginine, leucine) from Auspep (Parkville, Australia); furegrelate and SQ 29,548 ($[1S-[1\alpha,2\alpha(Z),3\alpha,4\alpha]]$ -7-[3-[[2-[(phenylamino)carnonyl]hydrazine]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid) from Cayman-Europe (Tallinn, Estonia). TRAM-34 was a generous gift from Dr H Wulff (University of California, Davis, USA). All stock solutions (100 mM) were prepared in dimethyl sulphoxide (DMSO) except L-NAME, apamin, iberiotoxin, papaverine and SLIGRL, which were dissolved in 0.9% NaCl, and indomethacin, which was dissolved in Na₂CO₃ (1 M); vehicle controls were performed when necessary.

Results

We have previously reported myogenic tone equivalent to about 14% of the maximal vasoconstriction induced in rat middle cerebral arteries by raising $[K^+]_o$ to 55 mM, and that the NOS inhibitor, L-NAME (100 μ M) further contracts the artery to *Circa* 70% of this maximum associated with smooth muscle depolarization of 12.8 \pm 0.7 mV (McNeish *et al.*, 2005). In the current study, in the presence of L-NAMEinduced vasoconstriction, SLIGRL induced EDHF-mediated hyperpolarization and relaxation to 19.6 \pm 3.1 mV and 80.9 \pm 6.7% (n=4, respectively). In agreement with our previous studies, this hyperpolarization and relaxation was abolished by the selective IK_{Ca} channel inhibitor TRAM-34 (to 1.2 \pm 0.8 mV and 6.0 \pm 1.8%, respectively, n=4).

Effect of inhibiting TP receptors or CYP 450 on L-NAME constriction and EDHF-mediated hyperpolarization and relaxation

The TP receptor antagonist ICI 192,605 ($100 \mu M$) reversed depolarization and contraction to L-NAME (by $12.9 \pm 2.9 \text{ mV}$, n=3 and $67.9 \pm 6.3\%$, n=7, respectively), but did not alter the EDHF-mediated hyperpolarization (n=7) and relaxation (n=9) to SLIGRL ($20 \mu M$; Figure 2a). In the presence of ICI 192,605, EDHF responses were now resistant to blockade of IK_{Ca} with $1 \mu M$ TRAM-34 (Figures 1b and 2a; n=4) and remained insensitive to blockade of SK_{Ca} with apamin (50 nM, Figure 2a; n=5). However, in combination, these blockers markedly attenuated the EDHF response (Figures 1c and 2a; n=10).


The structurally distinct TP receptor antagonist SQ 29,546 (10μ M) did not modify L-NAME-induced tone, but did have similar effects to ICI 192,605 against the EDHF response. In the presence of SQ 29,546 (Figure 2b), EDHF-mediated hyperpolarization (n=10) and relaxation (n=10) was not significantly altered (n=7). Neither apamin (50 nM; n=3) nor TRAM-34 (n=4) had a significant effect on the EDHF hyperpolarization and relaxation (Figure 2), but in combination abolished the response (Figure 2b; n=6).

The non-selective CYP450 inhibitor, 17-octadecynoic acid (17-ODYA) (10 μ M), did not alter L-NAME-induced constriction (total tone 4.2±0.4 and 4.0±0.4 mN in the absence and presence of 17-ODYA, respectively, n = 6), or EDHF-mediated hyperpolarization and relaxation (19.8±4.3 mV and 74.9±5.8%, versus 19.0±2.3 mV and 74.4±5.5%, respectively, n = 4). Furthermore, in the presence of 17-ODYA, TRAM-34 alone still effectively abolished EDHF responses (residual, 2.2±2.4 mV and 13.1±5.1%, n = 4).

Effect of TP receptor stimulation on endothelium-dependent hyperpolarization in the absence of L-NAME

With NO (basal) synthesis extant, endothelium-dependent hyperpolarization to SLIGRL ($20 \,\mu M$) in cerebral arteries reflects activation of both SK_{Ca} and IK_{Ca} channels (McNeish et al., 2006). In the present study, under similar conditions, the TP receptor agonist U46619 (5 nm) depolarized and contracted the cerebral arteries (by $7.2\pm2.8\,\mathrm{mV}$ and 3.5 ± 0.3 mN; n = 5 and n = 13, respectively). During constriction with U46619, SLIGRL-induced hyperpolarization (Figure 3a; n = 13) was resistant to apamin (n = 4) but partially inhibited by TRAM-34 (P < 0.01). The inhibitory action of TRAM-34 was not increased by the additional presence of apamin. The remaining, residual hyperpolarization was, however, attenuated by the inhibitor of BK_{Ca}, iberiotoxin (Figure 3, P < 0.001; n = 5). In Figure 3b, apamin and TRAM-34 alone or in combination did not affect relaxation to SLIGRL, reflecting the direct smooth muscle vasodilator action of NO in these vessels. However, a combination of apamin, TRAM-34 and iberiotoxin did significantly inhibit SLIGRL-induced relaxation (Figure 3b). This probably reflects block of NO action, as hyperpolarization (McNeish et al., 2006) and relaxation (unpublished observation) to the NO donor DEA-NONOate is inhibited by iberiotoxin in this artery.

Thromboxane A₂ inhibition of SK_{Ca} after NOS block AJ McNeish and CJ Garland



L-NAME (100 µM) and ICI 192,605 (100 µM) present throughout

Figure 1 Original recordings of EDHF-mediated relaxation (upper trace) and hyperpolarization (lower trace) from a rat middle cerebral artery preconstricted with the NOS inhibitor L-NAME (100 μ M) and in the presence of the of the TP inhibitor ICI 192,605 (100 μ M; **a**) also shown is the subsequent effects either of the IK_{Ca} channel inhibitor TRAM-34 (1 μ M) alone (**b**) or the combined blockade of IK_{Ca} and SK_{Ca} channels with TRAM-34 and apamin (50 nM; **c**) on the EDHF response. Dotted lines represent the control tension and resting membrane potential, respectively. In the presence of ICI 192,605, EDHF responses have a functional input from SK_{Ca}, as they were only blocked by the combination of TRAM-34 and apamin. Parallel lines (//) indicate a time break between separate recordings from a single vessel.




Figure 2 Histograms showing the effect of the structurally distinct TP antagonists ICI 193,605 (100μ M; **a** and SQ 29,548 (10μ M; **b**) on SLIGRL (20μ M)-induced, EDHF-mediated hyperpolarization (left panels) and relaxation (right panels) in rat middle cerebral artery preconstricted with the NOS inhibitor L-NAME (100μ M). Also shown is the effect of the IK_{Ca} blocker, TRAM-34 (1μ M) and the SK_{Ca} blocker apamin (50 nM), both alone and in combination. When TPs were inhibited, the EDHF response was only blocked by combined incubation of both TRAM-34 and apamin, indicating that there is a functional input from SK_{Ca} in this response. **P<0.01 and ***P<0.001 indicate a statistically significant difference from control.




Figure 3 Histograms showing the effect of the TxA₂ mimetic U46619 (5 nM) on hyperpolarization (**a**) and relaxation (**b**) produced by SLIGRL (20 μ M) in rat middle cerebral arteries that had not been treated with an NOS inhibitor. Also shown are the effects of the IK_{Ca} inhibitor TRAM-34 (1 μ M), the SK_{Ca} channel inhibitor, apamin (50 nM) and the BK_{Ca} inhibitor, iberiotoxin (lbTx; 100 nM) on these responses. TRAM-34 alone inhibited the SLIGRL-induced hyperpolarization, whereas apamin had no effect. Combination of TRAM-34 and apamin had no additional effect when compared to TRAM-34 alone. The combination of apamin, TRAM-34 and iberiotoxin did further attenuate hyperpolarization and relaxation. Relaxations were unaffected by apamin and TRAM-34 alone or in combination with apamin as these vessels are able to synthesize NO. The NO-dependent relaxation was affected by iberiotoxin. **P<0.01 and ***P<0.001 indicate a statistically significant difference from control.






Figure 4 Original traces showing SLIGRL (20μ M)-induced, EDHF-mediated relaxation (upper panels) and hyperpolarization (lower panels) in a rat middle cerebral artery treated with the NOS inhibitor L-NAME (100μ M) and the thromboxane synthase inhibitor, furegrelate (10μ M; **a**). Also shown is the additional effect of: (**b**) the IK_{Ca} inhibitor, TRAM-34 (1μ M); (**c**) the combination of TRAM-34 and the SK_{Ca} inhibitor, apamin (50 nM) and (**d**) the combination of TRAM-34, apamin and the BK_{Ca} inhibitor, iberiotoxin (100 nM). Dotted lines represent the control tension and membrane potential. Only the combination of apamin, TRAM-34 and iberiotoxin fully blocked the EDHF response, indicating that functional inputs from SK_{Ca}, IK_{Ca} and BK_{Ca} contribute to the EDHF response under these conditions. Parallel lines (//) indicate a time break between separate recordings from a single vessel.

*Effect of inhibiting TxA*² *synthase, cyclo-oxygenase or*

phospholipaseA₂ on L-NAME-induced tone and EDHF responses The thromboxane synthase inhibitor, furegrelate $(10 \,\mu\text{M})$, did not affect L-NAME-induced constriction $(5.0\pm0.4 \text{ and} 5.0\pm0.4 \text{ mN})$ before and after furegrelate treatment, respectively, n = 6). EDHF-mediated hyperpolarization (n = 5) and relaxation (n=5) evoked by SLIGRL (20 μ M) was also not significantly modified by furegrelate (Figure 5a; n=6) and TRAM-34 did not have any additional effect (Figures 4b and 5a; n=4). However, in combination, apamin and TRAM-34 did attenuate EDHF-mediated hyperpolarization (Figures 4c and 5a; P<0.05; n=5), but without significantly altering




Figure 5 Histograms showing the EDHF-mediated hyperpolarization (left panels) and relaxation (right panels) in the presence of the NOS inhibitor L-NAME (100 μ M) and either: (a) the thromboxane synthase inhibitor, furegrelate (10 μ M), or (b) the cyclo-oxygenase inhibitor indomethacin (10 μ M). Also shown are the effects of the IK_{Ca} inhibitor, TRAM-34 (1 μ M), the SK_{Ca} inhibitor apamin (50 nM) and the BK_{Ca} inhibitor iberiotoxin (IbTx; 100 nM). Only combined application of TRAM-34, apamin and iberiotoxin fully blocked the EDHF response in the presence of either furegrelate or indomethacin. **P*<0.05, ***P*<0.01 and ****P*<0.001 indicate a statistically significant difference from control.

relaxation (n = 5). In the additional presence of the BK_{Ca} channel inhibitor iberiotoxin (100 nM), EDHF responses were blocked (Figures 4d and 5a, P < 0.001; n = 4).

Control EDHF responses obtained in the presence of L-NAME alone (hyperpolarization of 26.0 ± 6.0 mV and relaxation of $84.6\pm4.7\%$, n=5) were unaffected by the addition of iberiotoxin (hyperpolarization of 21.2 ± 6.3 mV and relaxation of $75.8\pm4.2\%$, n=5, respectively).

Similar results were obtained after inhibition of cyclooxygenase with $10 \,\mu$ M indomethacin (Figure 5b). Indomethacin did not affect L-NAME-induced vasoconstriction or the EDHF response (tone of 5.0 ± 0.6 and 4.7 ± 0.4 mN, n = 6 and 11, before and after indomethacin treatment, respectively). TRAM-34 alone did not significantly depress EDHF-mediated hyperpolarization or relaxation (n = 10), but, in combination with apamin, TRAM-34 did significantly attenuate these responses (P < 0.05; n = 6). The residual response was blocked by the addition of iberiotoxin (Figure 5b; P < 0.05; n = 3).

The PLA₂ inhibitor AACOCF₃ (10 μ M; Figure 6) reversed L-NAME-induced tone by 85.6 \pm 3.8% and inhibited EDHF hyperpolarization and relaxation (27.7 \pm 6.0 mV and 72.0 \pm 7.4%, *n*=7, versus 9.4 \pm 3.5 mV and 32.7 \pm 15.0%, *n*=6, respectively; Figure 6b). The residual EDHF response was blocked by TRAM-34 alone (5.6 \pm 2.8 mV and 4.5 \pm 6.5%, respectively, *n*=4, *P*<0.05; Figure 6c).

Discussion

These data demonstrate that activation of TxA_2 receptors in the rat middle cerebral artery can explain the absence of SK_{Ca}

British Journal of Pharmacology (2007) 151 441-449

input to endothelium-dependent hyperpolarization when NO synthesis is inhibited. Furthermore, inhibition of NOS may result in an increase in TxA₂ synthesis, as inhibiting TxA₂ synthesis restores SK_{Ca} input as well as uncovering a previously unrecognized role for BK_{Ca} in the EDHF response. These results help to explain our previous observation that NO protects a functional input from SK_{Ca} in the rat middle cerebral artery (McNeish *et al.*, 2006) and provide a link to our demonstration that the stimulation of TP receptors inhibits SK_{Ca} function (Plane and Garland, 1996; Crane and Garland, 2004).

EDHF responses in the rat middle cerebral artery are unusual, in being dependent only on activation of IK_{Ca}. In most vessels that exhibit an EDHF response, inhibition of both SK_{Ca} and IK_{Ca} channels is necessary to block the EDHF response (Busse et al., 2002). Despite this difference, the rat middle cerebral artery does exhibit morphological features similar to other vessels, that is, both IK_{Ca} and SK_{Ca} channels are expressed within the endothelium (McNeish et al., 2006) and the endothelium is coupled to the smooth muscle layer by myo-endothelial gap junctions (McNeish et al., 2006; Sokoya et al., 2006). Furthermore, SK_{Ca} channels can contribute to endothelium-dependent hyperpolarization in the middle cerebral artery, but only when the vessels are still able to synthesize NO (McNeish et al., 2006). The NOdependent contribution of SK_{Ca} to endothelium-dependent hyperpolarization did not appear to involve a concomitant inhibition of IK_{Ca}, because in the presence of apamin, a normal, maximum hyperpolarization and relaxation was still evoked (McNeish et al., 2006). The mechanism responsible for the apparent ability of NO to protect SK_{Ca} function is,




Figure 6 Original traces showing SLIGRL (20μ M)-induced EDHF-mediated relaxation (upper traces) and hyperpolarization (lower traces) in a rat middle cerebral artery treated with the NOS inhibitor L-NAME (100μ M; **a**). Also shown is the effect of the PLA₂ inhibitor AACOCF3 (10μ M) on L-NAME-induced tone and the EDHF response (**b**) and the subsequent effect of IK_{Ca} blocker, TRAM-34 (1μ M) on the residual EDHF response (**c**). Dotted lines represent the control membrane potential and tension before addition of AACOCF3. AACOCF3 relaxed the L-NAME-induced tone as well as attenuating the EDHF response, the residual EDHF response was completely blocked by TRAM-34 alone. Parallel lines (//) indicate a time break between separate recordings from a single vessel.

however, unclear and may involve both a direct effect of NO and downstream signalling mediators such as cGMP-linked effects. For example, NO may directly interact with SK_{Ca} channels, as it does in smooth muscle of the rat fundus (Geeson *et al.*, 2002). Alternatively or additionally, as NO readily interacts with other signalling pathways, particularly those involving haem-containing enzymes and the metabolism of arachidonic acid, a protective role may reflect an interaction of the NO/cGMP pathway with factors elaborated within the artery wall.

One possibility is an alteration in the synthesis of 20-HETE, a potent vasoconstrictor derived from arachidonic acid by CYP450-dependent enzymes. 20-HETE is involved in myogenic constriction/autoregulation in cerebral vessels (Harder et al., 1994; Gebremedhin et al., 2000) and is also known to inhibit EDHF-mediated responses by reducing K_{Ca} function in small coronary arteries (Randriamboavonjy et al., 2005). Furthermore, synthesis of 20-HETE can be inhibited by NO binding to the haem active site of its synthetic enzyme (Minamiyama et al., 1997). However, despite the fact that 20-HETE has a role in myogenic tone, we failed to demonstrate any input to cerebral constriction after inhibition of NOS. The non-selective CYP450 inhibitor 17-octadecynoic acid (17-ODYA) did not alter the L-NAMEinduced constriction in the middle cerebral artery. Furthermore, 17-ODYA also failed to reveal any functional role for the SK_{Ca} channel in the EDHF response, as TRAM-34 alone was still able to abolish this response. This suggests that NO does not normally protect SK_{Ca} channel function by inhibiting the synthesis/function of 20-HETE or a related metabolite generated by CYP450-dependent enzymes.

Another autacoid that could affect K_{Ca} channel function is the potent vasoconstrictor and platelet activator TxA₂. As well as being involved in NOS-mediated vasoconstriction in rat middle cerebral arteries (Benyo et al., 1998; Lacza et al., 2001; Gonzales et al., 2005), we have previously shown that stimulation of TPs results in a fairly rapid loss of the SK_{Ca} component of EDHF hyperpolarization and associated relaxation in peripheral arteries of the rat (Crane and Garland, 2004). NO does inhibit the formation of TxA_2 , by binding to the haem active site of TxA₂ synthase (Wade and Fitzpatrick, 1997). It may also inhibit cyclo-oxygenase (Kanner et al., 1992), responsible for synthesizing the precursor of TxA₂ (and other prostaglandins), prostaglandin H_2 (PGH₂). In addition to inhibiting synthesis, NO is also known to desensitize the TP receptor through a PKGdependent mechanism (Reid and Kinsella, 2003). In the present study, L-NAME-induced constriction was significantly reduced by the TP receptor antagonist, ICI 192,605, indicating that receptor activation might account for at least some of the constriction following inhibition of NOS. In contrast, a structurally unrelated TP antagonist SQ 29,548 failed to alter L-NAME-induced constriction, suggesting that ICI 192,605 may have been acting non-selectively. Indeed, the concentration of ICI 192,605 used in this study (100 μ M) is known to have effects on prostaglandin E_2 (PGE₂) (EP) receptors, which may provide an explanation (Brewster et al., 1988). However, in vessels pretreated with L-NAME, both of the TP receptor antagonists uncovered a functional role for the SK_{Ca} channel in the EDHF response. Simultaneous block of both SK_{Ca} and IK_{Ca} channels with apamin and TRAM-34 was necessary to abolish the response as the functional ability of either channel appeared sufficient to elicit adequate hyperpolarization for full EDHF-mediated relaxation. Therefore, stimulation of TP receptors could explain the loss of the SK_{Ca}-dependent component of endotheliumdependent hyperpolarization after inhibition of NOS. This

447

suggestion is supported by the observation that activation of TP with U46619 abolishes the SK_{Ca} component of endothelium-dependent hyperpolarization, in arteries still able to synthesize NO. NO-dependent inhibition of TPs appears to depend on activation of PKG (Reid and Kinsella, 2003), which may explain our previous observation that ODQ (1*H*-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one), an inhibitor of soluble guanylate cyclase, revealed endothelium-dependent hyperpolarization mainly dependent upon IK_{Ca} (McNeish *et al.*, 2006). The possible involvement of cGMP-mediated effects in the regulation of SK_{Ca} channel function is a subject of ongoing investigation.

As stimulation of TPs appeared to account for the loss of SK_{Ca} function in arteries treated with an NOS inhibitor, we investigated if receptor stimulation reflected an increased synthesis of TxA₂ (or its precursor PGH₂, which can also stimulate these receptors) as opposed to an inhibitory action of NO/cGMP-dependent signalling on TPs. The former appeared to be the case, as inhibition of TxA₂ synthase with furegrelate or inhibition of cyclo-oxygenase (to inhibit synthesis of PGH₂ and thus TxA₂) with indomethacin each revealed a role for SK_{Ca} channels in the EDHF response. Neither treatment had any effect on the L-NAME-induced constriction, again indicating that stimulation of TP receptors does not form a major component of this response. Interestingly, pretreatment with either indomethacin or furegrelate also revealed a role for $\ensuremath{\mathsf{BK}_{\mathsf{Ca}}}$ in the EDHF response. The explanation for this unexpected observation is the subject of ongoing investigation. One possibility is that altering the prostanoid profile in the vessel wall uncovers an eicosanoid pathway able to directly activate BK_{Ca} on the smooth muscle cells in this artery (McNeish et al., 2006).

The observation that stimulation of either TP receptors or 20-HETE did not appear to contribute to the contraction following inhibition of NOS was surprising, as both signalling pathways have previously been implicated in this response (Harder et al., 1994; Benyo et al., 1998; Lacza et al., 2001). However, our data do indicate that constriction involves a metabolite of arachidonic acid, as the phopholipase A₂ (PLA₂) inhibitor AACOCF₃ fully reversed L-NAMEinduced constriction. Interestingly, the EDHF response was also attenuated by inhibition of PLA₂, which is consistent with previous observations in the rat middle cerebral artery (You et al., 2002). However, a significant EDHF response remained after treatment with AACOCF₃ and was abolished by TRAM-34. Overall, these observations suggest there are at least two components of the EDHF response in the rat middle cerebral artery. One component appears to involve a metabolite of arachidonic acid. A recent study by You et al. (2005) appears to rule out the involvement of metabolites of either the lipoxygenase (epoxyeicosatrienoic acids, EETs) or epoxgenase pathways (hydroxyeicosatetraenoic acids, HETEs) in rat middle cerebral arteries (You et al., 2005), so the identity of such an active metabolite remains uncertain. Other components of the EDHF response appear to rely solely upon the activation of endothelial K_{Ca} channels, and may lead to smooth muscle hyperpolarization/relaxation through an increase in extracellular [K⁺] (McNeish *et al.*, 2005) and/or a direct transfer of hyperpolarization via

myoendothelial gap junctions (McNeish *et al.*, 2006; Sokoya *et al.*, 2006).

In summary, inhibition of NOS leads to pronounced constriction in cerebral arteries that appears to involve an unidentified metabolite of arachidonic acid. This metabolite does not appear to be either of the potent endogenous vasoconstrictors 20-HETE or TxA2. However, block of the SK_{Ca}-mediated component of endothelium-dependent (EDHF) hyperpolarization, which follows inhibition of NOS, can be reversed by inhibiting TPs or by reducing the synthesis of TxA₂. Therefore, increased thromboxane signalling after inhibition of NOS may underlie blockade of a fundamental part of the EDHF response in these arteries. The fact that loss of NO signalling can disrupt the EDHF pathway and associated vasodilatation, through increased activity of the potent vasoconstrictor/platelet activator TxA₂, is likely to be of fundamental relevance in disease states where NO release is known to be compromised.

Acknowledgements

This work was supported by the British Heart Foundation.

Conflict of interest

The authors state no conflict of interest.

References

- Benyo Z, Gorlach C, Wahl M (1998). Involvement of thromboxane A2 in the mediation of the contractile effect induced by inhibition of nitric oxide synthesis in isolated rat middle cerebral arteries. *J Cereb Blood Flow Metab* **18**: 616–618.
- Brewster AG, Brown GR, Foubister AJ, Jessup R, Smithers MJ (1988). The synthesis of a novel thromboxane receptor antagonist 4(*Z*)-6-(2-*o*-chlorophenyl-4-*o*-hydroxyphenyl-1,3-dioxan-*cis*-5-yl) hexenoic acid ICI 192605. *Prostaglandins* **36**: 173–178.
- Burnham MP, Bychkov R, Feletou M, Richards GR, Vanhoutte PM, Weston AH *et al.* (2002). Characterization of an apamin-sensitive small-conductance Ca²⁺-activated K⁺ channel in porcine coronary artery endothelium: relevance to EDHF. *Br J Pharmacol* **135**: 1133–1143.
- Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH (2002). EDHF: bringing the concepts together. *Trends Pharmacol Sci* **23**: 374–380.
- Bychkov R, Burnham MP, Richards GR, Edwards G, Weston AH, Feletou M *et al.* (2002). Characterization of a charybdotoxinsensitive intermediate conductance Ca²⁺-activated K⁺ channel in porcine coronary endothelium: relevance to EDHF. *Br J Pharmacol* **137**: 1346–1354.
- Crane GJ, Gallagher N, Dora KA, Garland CJ (2003). Small- and intermediate-conductance calcium-activated K⁺ channels provide different facets of endothelium-dependent hyperpolarization in rat mesenteric artery. *J Physiol (Lond)* **553**: 183–189.
- Crane GJ, Garland CJ (2004). Thromboxane receptor stimulation associated with loss of SKCa activity and reduced EDHF responses in the rat isolated mesenteric artery. *Br J Pharmacol* **142**: 43–50.
- Feletou M, Vanhoutte PM (2006). Endothelium-derived hyperpolarizing factor: where are we now? *Arterioscler Thromb Vasc Biol* 26: 1215–1225.
- Garland CJ, McPherson GA (1992). Evidence that nitric oxide does not mediate the hyperpolarisation and relaxation to acetylcholine in the rat small mesenteric artery. *Br J Pharmacol* **105**: 429–435.

- Gebremedhin D, Lange AR, Lowry TF, Taheri MR, Birks EK, Hudetz AG *et al.* (2000). Production of 20-HETE and its role in autoregulation of cerebral blood flow. *Circ Res* **87**: 60–65.
- Geeson J, Larsson K, Hourani SM, Toms NJ (2002). Sodium nitroprusside-induced rat fundus relaxation is ryanodine-sensitive and involves L-type Ca^{2+} channel and small conductance Ca(2+)sensitive K⁺ channel components. *Auton Autacoid Pharmacol* 22: 297–301.
- Gonzales RJ, Ghaffari AA, Duckles SP, Krause DN (2005). Testosterone treatment increases thromboxane function in rat cerebral arteries. *Am J Physiol* **289**: H578–H585.
- Harder DR, Gebremedhin D, Narayanan J, Jefcoat C, Falck JR, Campbell WB *et al.* (1994). Formation and action of a P-450 4A metabolite of arachidonic acid in cat cerebral microvessels. *Am J Physiol* **266**: H2098–H2107.
- Kanner J, Harel S, Granit R (1992). Nitric oxide, an inhibitor of lipid oxidation by lipoxygenase, cyclooxygenase and hemoglobin. *Lipids* **27**: 46–49.
- Lacza Z, Herman P, Gorlach C, Hortobagyi T, Sandor P, Wahl M *et al.* (2001). NO synthase blockade induces chaotic cerebral vasomotion via activation of thromboxane receptors. *Stroke* **32**: 2609–2614.
- Marrelli SP, Eckmann MS, Hunte MS (2003). Role of endothelial intermediate conductance KCa channels in cerebral EDHF-mediated dilations. *Am J Physiol* **285**: H1590–H1599.
- McNeish AJ, Dora KA, Garland CJ (2005). Possible role for K⁺ in endothelium-derived hyperpolarizing factor-linked dilatation in rat middle cerebral artery. *Stroke* **36**: 1526–1532.
- McNeish AJ, Sandow SL, Neylon CB, Chen MX, Dora KA, Garland CJ (2006). Evidence for involvement of both IKCa and SKCa channels in hyperpolarizing responses of the rat middle cerebral artery. *Stroke* **37**: 1277–1282.
- Minamiyama Y, Takemura S, Imaoka S, Funae Y, Tanimoto Y, Inoue M (1997). Irreversible inhibition of cytochrome P450 by nitric oxide. *J Pharmacol Exp Ther* **283**: 1479–1485.

- Plane F, Garland CJ (1996). Influence of contractile agonists on the mechanism of endothelium-dependent relaxation in rat isolated mesenteric artery. *Br J Pharmacol* **119**: 191–193.
- Randriamboavonjy V, Kiss L, Falck JR, Busse R, Fleming I (2005). The synthesis of 20-HETE in small porcine coronary arteries antagonizes EDHF-mediated relaxation. *Cardiovas Res* **65**: 487–494.
- Reid HM, Kinsella BT (2003). The {alpha}, but not the {beta}, isoform of the human thromboxane A2 receptor is a target for nitric oxide-mediated desensitization: independent modulation of TP{alpha} signaling by nitric oxide and prostacyclin. *J Biol Chem* **278**: 51190–51202.
- Sokoya EM, Burns AR, Setiawan CT, Coleman HA, Parkington HC, Tare M (2006). Evidence for the involvement of myoendothelial gap junctions in EDHF-mediated relaxation in the rat middle cerebral artery. *Am J Physiol* **291**: H385–H393.
- Wade ML, Fitzpatrick FA (1997). Nitric oxide modulates the activity of the hemoproteins prostaglandin I2 synthase and thromboxane A2 synthase. *Arch Biochem Biophys* **347**: 174–180.
- Walker SD, Dora KA, Ings NT, Crane GJ, Garland CJ (2001). Activation of endothelial cell IKCa with 1-ethyl-2-benzimidazolinone evokes smooth muscle hyperpolarization in rat isolated mesenteric artery. *Br J Pharmacol* 134: 1548–1554.
- You J, Golding EM, Bryan Jr RM (2005). Arachidonic acid metabolites, hydrogen peroxide, and EDHF in cerebral arteries. *Am J Physiol* 289: H1077–H1083.
- You J, Marrelli SP, Bryan Jr RM (2002). Role of cytoplasmic phospholipase A2 in endothelium-derived hyperpolarizing factor dilations of rat middle cerebral arteries. J Cereb Blood Flow Metab 22: 1239–1247.
- Zygmunt PM, Plane F, Paulsson M, Garland CJ, Hogestatt ED (1998). Interactions between endothelium-derived relaxing factors in the rat hepatic artery: focus on regulation of EDHF. *Br J Pharmacol* **124**: 992–1000.